Recent clinical research indicates that GLP-1 receptor agonists deliver significant cardiovascular benefits beyond managing diabetes and aiding weight loss.
A meta-analysis of 60,000 patients revealed a 14% relative reduction in major adverse cardiovascular events and a 12% drop in all-cause mortality.
The SELECT trial demonstrated that semaglutide reduced the risk of major cardiovascular events by 20% over three years in non-diabetic individuals.